UCSF and UT Southwestern researchers have shown that direct reprogramming of cardiac fibroblasts into cardiomyocyte-like cells is feasible in vivo and could promote the recovery of cardiac function after myocardial infarction. LoneStar Heart has exclusively licensed the UT Southwestern technology.